| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | Adrian |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | Adrian |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | Alma |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | Alma |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | Alma |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | Alma |
| A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial | Phase 2 | University of Michigan Rogel Cancer Center | Ann Arbor |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | Ann Arbor |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | Ann Arbor |
| A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | N/A | University of Michigan Rogel Cancer Center | Ann Arbor |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | Ann Arbor |
| A Study of PHST001 in Advanced Solid Tumors | Phase 1 | Pheast Therapeutics | Ann Arbor |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Phase 1/2 | LigaChem Biosciences, Inc. | Ann Arbor |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | Phase 2 | ALX Oncology Inc. | Ann Arbor |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | Ann Arbor |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | Ann Arbor |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | Ann Arbor |
| Breast Cancer Resiliency Through Exercise Program (B-REP) | N/A | University of Michigan Rogel Cancer Center | Ann Arbor |
| CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer | N/A | University of Michigan Rogel Cancer Center | Ann Arbor |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | Ann Arbor |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | — | Tempus AI | Ann Arbor |
| Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | Phase 2 | National Cancer Institute (NCI) | Ann Arbor |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | Ann Arbor |
| Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial | Phase 2 | University of Michigan Rogel Cancer Center | Ann Arbor |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | Phase 2 | National Cancer Institute (NCI) | Ann Arbor |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | Ann Arbor |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | Ann Arbor |
| Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | Phase 4 | University of Michigan Rogel Cancer Center | Ann Arbor |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | Ann Arbor |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | Phase 2 | Oana Danciu | Ann Arbor |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | Ann Arbor |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | Ann Arbor |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | Ann Arbor |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | Ann Arbor |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | Ann Arbor |
| Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial | Phase 3 | Alliance for Clinical Trials in Oncology | Ann Arbor |
| The Cancer of the Pancreas Screening-5 CAPS5)Study | Phase 3 | Johns Hopkins University | Ann Arbor |
| A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer | N/A | Barbara Ann Karmanos Cancer Institute | Bay City |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | Big Rapids |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | Phase 3 | National Cancer Institute (NCI) | Brighton |
| The Vanguard Study: Testing a New Way to Screen for Cancer | N/A | National Cancer Institute (NCI) | Brownstown |
| A Study of the TheraBionic P1 Device in Breast Cancer | N/A | Barbara Ann Karmanos Cancer Institute | Clarkston |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | Dearborn |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | Dearborn |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Phase 1/2 | BioNTech SE | Detroit |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | Detroit |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | Detroit |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase 3 | AstraZeneca | Detroit |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | Detroit |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | Phase 3 | Hoffmann-La Roche | Detroit |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | Detroit |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | Detroit |
| A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. | N/A | Barbara Ann Karmanos Cancer Institute | Detroit |
| A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Phase 1/2 | Day One Biopharmaceuticals, Inc. | Detroit |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | Phase 1 | IDEAYA Biosciences | Detroit |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | Detroit |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | Detroit |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | Detroit |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | Detroit |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | Detroit |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | Detroit |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | Detroit |
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 2 | Bayer | Detroit |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | Phase 4 | AstraZeneca | Detroit |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeOne Medicines | Detroit |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | Phase 3 | BeOne Medicines | Detroit |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | Detroit |
| Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors | N/A | Barbara Ann Karmanos Cancer Institute | Detroit |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Phase 1/2 | Accent Therapeutics | Detroit |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | Detroit |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Phase 1/2 | Jacobio Pharmaceuticals Co., Ltd. | Detroit |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | Detroit |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Phase 1/2 | Incyclix Bio | Detroit |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Phase 1/2 | Ellipses Pharma | Detroit |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | Detroit |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | Detroit |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | Detroit |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | Detroit |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | N/A | Natera, Inc. | Detroit |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | Detroit |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | Detroit |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | Detroit |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | Detroit |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | Detroit |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | Detroit |
| A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | Phase 1/2 | Hummingbird Bioscience | Farmington Hills |
| Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer | Phase 2 | Proton Collaborative Group | Flint |
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Phase 1/2 | Radiopharm Theranostics, Ltd | Grand Rapids |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | Grand Rapids |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Phase 2 | GlaxoSmithKline | Grand Rapids |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | Grand Rapids |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | Grand Rapids |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | Grand Rapids |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | Grand Rapids |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | Grand Rapids |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Phase 1/2 | Tanabe Pharma America, Inc. | Grand Rapids |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | Grand Rapids |
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | Phase 1 | Eli Lilly and Company | Grand Rapids |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | Grand Rapids |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Phase 1 | Cogent Biosciences, Inc. | Grand Rapids |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | Grand Rapids |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | Phase 1 | Pfizer | Grand Rapids |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Phase 1 | Avacta Life Sciences Ltd | Grand Rapids |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | LeonaBio | Grand Rapids |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | Grand Rapids |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Phase 1 | Olema Pharmaceuticals, Inc. | Grand Rapids |
| Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer | Phase 1 | Immunomic Therapeutics, Inc. | Grand Rapids |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | Grand Rapids |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Phase 1 | Novartis Pharmaceuticals | Grand Rapids |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | Phase 1/2 | Artios Pharma Ltd | Grand Rapids |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Phase 1 | AbbVie | Grand Rapids |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | Phase 1 | AbbVie | Grand Rapids |
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | Phase 1/2 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Grand Rapids |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | Phase 1/2 | Pfizer | Grand Rapids |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | Grosse Pointe Woods |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | Lansing |
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | Phase 1 | TerSera Therapeutics LLC | Royal Oak |
| Quantitative MRI Assessment of Breast Cancer Therapy Response | — | Corewell Health East | Royal Oak |
| The PREDICT Registry: | — | PreludeDx | Royal Oak |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | — | M.D. Anderson Cancer Center | Saginaw |
| A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) | Phase 3 | Genentech, Inc. | Sterling Heights |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | Sterling Heights |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | Ypsilanti |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | Phase 1/2 | SynDevRx, Inc. | Ypsilanti |